Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Renee Thompson

Physician Assistant Hartford, CT Physician Assistant

NPI 1659837771 CMS profile 10776968

490 Blue Hills Ave, Hartford, CT 06112

Open in the dashboard

General payments

$9,207

151 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,562 paid to institutions, not to them · program years 2021–2023

Through program year 2025, Renee Thompson of Hartford, CT is reported in the CMS Open Payments database as having received $9,207 across 151 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $4,562 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,094 44
2024 General $588 40
2023 General $718 19
2022 General $3,756 31
2021 General $3,051 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Renee Thompson
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Renee Thompson were reported at $1,094. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Renee Thompson Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,051 $132 $37–$438 $132
2022 $3,756 $155 $48–$522 $149
2023 $718 $167 $52–$557 $160
2024 $588 $178 $55–$600 $164
2025 $1,094 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. E.R. Squibb & Sons, L.L.C. $2,071 3 payments
  2. Biogen, Inc. $1,913 46 payments
  3. Celgene Corporation $1,428 15 payments
  4. EMD Serono, Inc. $1,392 11 payments
  5. Janssen Pharmaceuticals, Inc $600 1 payment
  6. TG Therapeutics, Inc. $547 29 payments
  7. Novartis Pharmaceuticals Corporation $370 24 payments
  8. Genzyme Corporation $365 3 payments
  9. Genentech, Inc. $185 7 payments
  10. Amgen Inc. $177 6 payments
  11. Other $160 6 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $4,430 7 payments
  2. Food and Beverage $2,989 135 payments
  3. Travel and Lodging $1,404 5 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $265 2 payments
  5. Education $119 2 payments
Products named General payments · program years 2021–2025
  1. TYSABRI $1,543 26 payments
  2. BRIUMVI $547 29 payments
  3. VUMERITY Neurology $347 24 payments
  4. KESIMPTA $287 19 payments
  5. LEMTRADA $265 2 payments
  6. ZEPOSIA $184 8 payments
  7. UPLIZNA $177 6 payments
  8. OCREVUS $153 6 payments
  9. VUMERITY Neurology $147 13 payments
  10. AUBAGIO $100 1 payment
  11. Other $326 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,071

Median for Physician Assistant: 241

Drug cost

$3,913,839

Median for Physician Assistant: $4,110

Branded share of claims

36.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kesimpta Pen Ofatumumab Brand 121 $1,183,710
Copaxone Glatiramer Acetate Brand 83 $478,899
Avonex (4 Pack) Interferon Beta-1a Brand 38 $461,453
Aubagio Teriflunomide Brand 33 $426,582
Vumerity Diroximel Fumarate Brand 19 $239,656
Teriflunomide Generic 84 $239,190
Plegridy Pen Peginterferon Beta-1a Brand 25 $234,055
Fingolimod Fingolimod Hcl Brand 74 $157,742
Avonex Pen (4 Pack) Interferon Beta-1a Brand 19 $152,977
Tysabri Natalizumab Brand 12 $99,394

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$224,620

Medicare's payments for the services billed

Medicare patients

125

Average age 61

Services billed

9,357

89 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 50%
Depression 47%
Arthritis 44%
Diabetes 22%
Osteoporosis 16%
Ischemic heart disease 12%
Heart failure 10%
COPD 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
  • Novartis Pharmaceuticals Corporation $145
$145 121 —
VUMERITY
  • Biogen, Inc. $130
$130 19 —
ZEPOSIA
  • Celgene Corporation $107
$107 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $67
$67 — —
BRIUMVI
  • TG Therapeutics, Inc. $41
$41 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

151 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record